Randomized trial shows NAC treatment reduces inflammatory markers and improves nutritional status in hemodialysis patients, suggesting benefits of anti-inflammatory therapy.
Key Points
NAC treatment significantly lowers inflammatory markers and improves hemoglobin levels in hemodialysis patients.
After 3 months, h s-CRP levels decreased (P<0.01), while serum albumin levels increased (P<0.01).
Randomized controlled trial involved 71 patients on hemodialysis for more than 6 months, assessing various inflammatory and nutritional indicators.
Results indicate NAC's potential as an effective anti-inflammatory therapy, particularly benefiting female patients.